2019 Publications

Silica-associated lung disease: An old-world exposure in modern industries. View article. 2019. Barnes, H, Goh, NSL, Leong, TL, Hoy, R. Respirology. 2019; 24: 1165– 1175. https://doi.org/10.1111/resp.13695

Longevity of pulmonary rehabilitation benefit for chronic obstructive pulmonary disease-health care utilisation in the subsequent 2 years. View article. 2019. Walsh J.R., Pegg J., Yerkovich S.T., Morris N., McKeough Z.J., Comans T., Paratz J.D., Chambers D.C. BMJ Open Respiratory Research 6(1).

The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. View article. 2019. Solomon J.J., Danoff S.K., Goldberg H.J., Woodhead F., Kolb M., Chambers D.C., (…) Rosas I.O., on behalf of the Trail Network. Advances in Therapy. 36(11).

Fibulin-1c regulates transforming growth factor-b activation in pulmonary tissue fibrosis. View article. 2019. Liu G, (…) Knight DA, Burgess JK, Hansbro PM. JCI Insight, 4(16): e124529. 

A pilot randomised, controlled trial of ambulatory oxygen versus air via portable concentrator in fibrotic interstitial lung disease. View article. 2019. Khor YH, Goh N, Miller B, Glaspole I, Holland AE, McDonald CF. American Journal of Respiratory and Critical Care Medicine, 199.

Exertional desaturation and prescription of ambulatory oxygen therapy in ILD. View article. 2019. Khor YH, Goh NSL, Miller B, Glaspole I, Holland AE, McDonald CF. Respiratory Care, 64(3):299-306. doi: 10.4187/respcare.06334.

Understanding the patient’s experience of care in Idiopathic Pulmonary Fibrosis. View article. 2019. Burnett K, Glaspole I, Holland AE. Respirology. 24(3):270-277. doi: 10.1111/resp.13414.

Effective delivery of ambulatory oxygen in interstitial lung disease – a crossover trial. View article. 2019. Hoffman M, McDonald C, Corte T, Chambers D, Ekstrom M, Glaspole I, Goh N, Holland A. European Respiratory Journal 54:2. doi: 10.1183/13993003.congress-2019.PA1226.

Sharing experiences and offering mutual support: An evaluation of the Peer Connect Service for people with pulmonary fibrosis. View article. 2019. Holland AE, Lee J, Maloney J, Walsh J.  American Journal of Respiratory and Critical Care Medicine. 199:2.

Shared experiences, mutual support: Peer Connect Service for Pulmonary Fibrosis. View article. 2019. Holland A, Lee J, Maloney J, Walsh J. Respirology. 24:33.

Prognosis of adults with idiopathic pulmonary fibrosis without effective therapies: A systematic review and meta-analysis. View article. 2019. Khor YH, Barnes H, Ng Y, Goh N, McDonald CF, Holland AE. American Journal of Respiratory and Critical Care Medicine. 199:2.

Comprehensive pulmonary rehabilitation for interstitial lung disease: A consensus approach to identify core education topics. View article. 2019. Holland A.E., Watson A., Glaspole I. Patient Education and Counseling 102(6)

Nintedanib in patients with Idiopathic Pulmonary Fibrosis: Safety and tolerability. View article. 2019. Glaspole I, Lancaster L, Hernandez P, Inoue Y et al. Respirology, 24:34.

Baseline inflammatory markers and survival in patients with Interstitial lung disease. View article. 2019. Hatch M, Goh N, Khor Y. Respirology 24:167.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. View article. 2019. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, (…) Wells AU. Lancet Respiratory Medicine. 7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4.

Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). View article. 2019. Jee AS, Corte TJ. Drugs. 79(14):1511-1528. doi: 10.1007/s40265-019-01178-x.

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. View article. 2019. Moodley YP, Corte TJ, Oliver BG, Glaspole IN, Livk A, Ito J, Peters K, Lipscombe R, Casey T, Tan DBA. Respirology. 24(11):1111-1114. doi: 10.1111/resp.13668. 

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. View article. 2019. Maher TM, (…) Jenkins RG; INMARK trial investigators. Lancet Respiratory Medicine. 7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. 

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. View article. 2019. Troy LK, Grainge C, Corte T, (…) Lau EMT; COLDICE Investigator Team. BMJ Open Respiratory Research. 6(1):e000443. doi: 10.1136/bmjresp-2019-000443.

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSISÂ trials. View article. 2019. Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, Corte TJ. European Respiratory Journal. 54(3):1801797. doi: 10.1183/13993003.01797-2018.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. View article. 2019. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, …. Corte TJ, (…) Wells AU.  American Journal of Respiratory and Critical Care Medicine. 200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease – frontiers and horizons. View article. 2019. Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, Corte TJ. Pharmacology and Therapeutics. 202:40-52. doi: 10.1016/j.pharmthera.2019.05.014.

Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. View article. 2019. Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA; O2 Delphi Collaborators. European Respiratory Journal. 54(2):1900421. doi: 10.1183/13993003.00421-2019. 

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. View article. 2019. Jo HE, Corte TJ, Glaspole I, Grainge C, Hopkins PMA, Moodley Y, Reynolds PN, (…) Goh NS. BMC Pulmonary Medicine. 19(1):84. doi: 10.1186/s12890-019-0846-2.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. View article. 2019. Moore C, (…) Corte TJ, Glaspole I, Prele C, et al. American Journal of Respiratory and Critical Care Medicine. 200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

Patient Registries in Idiopathic Pulmonary Fibrosis. View article. 2019. Culver DA, Behr J, Belperio JA, Corte TJ, (…) Kim HJ. American Journal of Respiratory and Critical Care Medicine. 200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease. View article. 2019. Troy LK, Young IH, Lau EMT, Wong KKH, Yee BJ, Torzillo PJ, Corte TJ. Respirology. 24(10):996-1004. doi: 10.1111/resp.13549. 

Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. View article. 2019. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. ERJ Open Research. 5:00118-2019.

Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. View article. 2019. Burgess A, Goon K, Brannan JD, Attia J, Palazzi K, Oldmeadow C, Corte TJ, Glaspole I, Goh N, Keir G, Allan H, Chapman S, Cooper W, Ellis S, Hopkins P, Moodley Y, Reynolds P, Zappala C, Macansh S, Grainge C. Respirology. 24(10):988-995. doi: 10.1111/resp.13540. 

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. View article. 2019. Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, (…) Corte TJ. Respirology. 24(4):361-368. doi: 10.1111/resp.13427. 

Sustained and regulated gene expression by Tet-inducible “all-in-one” retroviral vectors containing the HNRPA2B1-CBX3 UCOE®. View article. 2019. Cullmann, K., Blokland, K. E. C., Sebe, A., Schenk, F., Ivics, Z., Heinz, N., & Modlich, U. Biomaterials, 192, 486-499.

STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. View article. 2019. Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Wei, L., Schuliga, M., Jaffar, J., (…) Knight, D. A. American Journal of Respiratory Cell and Molecular Biology, 61(1), 61-73.

Extracellular vesicles in lung health, disease, and therapy. View article. 2019. McVey, M. J., Maishan, M., Blokland, K. E. C., Bartlett, N., & Kuebler, W. M. American Journal of Physiology – Lung Cellular and Molecular Physiology, 316(6), L977-L989.

Inspiratory muscle training reduces dyspnea during activities of daily living and improves inspiratory muscle function and quality of life in patients with advanced lung disease. View article. 2019. Hoffman M, Augusto VM, Eduardo DS, Silveira BMF, Lemos MD, Parreira VF. Physiotherapy Theory Practice. 20:1-11

Therapeutic burden in interstitial lung disease: lessons to learn. View article. 2019. Khor YH, Glaspole I, Goh NSL. Respirology. 24(6):566-571. 

Factors predicting progression of exercise training loads in people with interstitial lung disease. View article. 2019. Nakazawa A, Dowman LM, Cox NS, McDonald CF, Hill CJ, Lee AL, Holland AE. European Respiratory Journal Open Research. 5(4). doi: 10.1183/23120541.00245-2018. 

The role of pathological aging in cardiac and pulmonary fibrosis. View article. 2019. Murtha L.A., (…) Knight D.A., Boyle A.J. Aging and Disease 10(2).

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. View article. 2019. Nathan S.D., Costabel U., Glaspole I., Glassberg M.K., Lancaster L.H., Lederer D.J., Pereira C.A., Trzaskoma B., Morgenthien E.A., Limb S.L., Wells A.U. Chest 155(4).

Comprehensive supportive care for patients with fibrosing interstitial lung disease. View article. 2019. Wijsenbeek M.S., Holland A.E., Swigris J.J., Renzoni E.A. American Journal of Respiratory and Critical Care Medicine 200(2)

Residential exposure to outdoor air pollution and post-bronchodilator lung function deficits in mid-adult life. View article. 2019. Perret J.L., (…) Walters E.H., Abramson M.J., Dharmage S.C. American Journal of Respiratory and Critical Care Medicine 200(1)

Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses. View article. 2019. Granger C.L., Morris N.R., Holland A.E. Respirology 24(9)

Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative. View article. 2019. Mackintosh J.A., Munsif M., Ranzenbacher L., Thomson C., Musk M., Snell G., Glanville A., Chambers D.C., Hopkins P. Journal of Heart and Lung Transplantation 38(5)

Considerations in the diagnosis of idiopathic pulmonary fibrosis. View article. 2019. Moodley Y. American Journal of Respiratory and Critical Care Medicine 199(5)

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. View article. 2019. Crestani B., Huggins J.T., Kaye M., Costabel U., Glaspole I., Ogura T., Song J.W., Stansen W., Quaresma M., Stowasser S., Kreuter M. The Lancet Respiratory Medicine 7(1)

Transcriptomics and single-cell RNA-sequencing. View article. 2019. Chambers D.C., Carew A.M., Lukowski S.W., Powell J.E. Respirology 24(1).

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. View article. 2019. Moodley YP, Corte TJ, Oliver BG, Glaspole IN, Livk A, Ito J, Peters K, Lipscombe R, Casey T, Tan DBA. Respirology 21(7).